Literature DB >> 11311644

Survival of childhood lymphomas in Europe, 1978--1992: a report from the EUROCARE study.

G Pastore1, C Magnani, A Verdecchia, A Pession, S Viscomi, J W Coebergh.   

Abstract

In most developed countries, malignant lymphomas account for 10--15% of all cancers occurring among children aged 0--14 years. The present study estimates survival after a diagnosis of lymphoma in childhood, based on the EUROCARE II database which includes 34 population-based cancer registries from 17 European countries. The survival pattern of children with malignant lymphoma diagnosed in 1985--1989 is reported, as well as the time trends since 1978. The analyses focus on Hodgkin's disease (HD, 1696 cases) and on non-Hodgkin's lymphoma (NHL, 2255 cases including Burkitt's lymphoma and unspecified lymphomas). For HD, the European weighted average 5-year survival rate was 93% (95% confidence interval (CI) 82--98) in 1985--1989. The survival rates were not affected by either age or gender. 5-year survival rates ranged from 68% (95% CI 34--90) in Estonia to 96% (95% CI 92--98) in Germany and 100% (95% CI 57--100) in Slovenia. Multivariate analyses for the time period 1978--1989 gave little suggestion of an improvement in survival over the later time periods of diagnosis. For NHL, the European weighted average 5-year survival rate was 74% (95% CI 67--80) in 1985--1989. Gender did not influence the survival rate. Children in the age group 0--4 years had a poorer prognosis compared with older cases (5-year rate: 66% versus 77% in the pool). 5-year survival rates ranged from 53% (95% CI 30--76) (Estonia) to 83% (95% CI 62--94) in France and 83% (95% CI 66--92) in Scotland. Multivariate analysis show a decreasing HR for the more recent periods of diagnosis from 1 in 1978--1981 to 0.67 (95% CI 0.56--0.79) in 1982--1985 to 0.48 (95% CI 0.40--0.57) in 1986--1989. Exploratory analysis, conducted including the cancer registries which provided cases diagnosed until 1992, show a positive trend over time for both types of lymphoma.

Entities:  

Mesh:

Year:  2001        PMID: 11311644     DOI: 10.1016/s0959-8049(01)00002-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Time trends and prognostic factors for survival from childhood cancer: a report from the Childhood Cancer Registry of Piedmont (Italy).

Authors:  Elisa Dama; Guido Pastore; Maria Luisa Mosso; Milena Maria Maule; Luisa Zuccolo; Corrado Magnani; Franco Merletti
Journal:  Eur J Pediatr       Date:  2006-01-13       Impact factor: 3.183

2.  Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.

Authors:  L Annemans; K Moeremans; M Lamotte; J Garcia Conde; H van den Berg; H Myint; R Pieters; A Uyttebroeck
Journal:  Support Care Cancer       Date:  2003-02-04       Impact factor: 3.603

Review 3.  Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  A J Swerdlow
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

Review 4.  The role of radiology in head and neck tumours in children.

Authors:  Claire Lloyd; Kieran McHugh
Journal:  Cancer Imaging       Date:  2010-03-03       Impact factor: 3.909

5.  Hodgkin lymphoma in childhood: clinicopathological features and therapy outcome at 2 centers from a developing country.

Authors:  Laila M Sherief; Usama R Elsafy; Elhamy R Abdelkhalek; Naglaa M Kamal; Rabab Elbehedy; Tamer H Hassan; Hanan S Sherbiny; Mohamed R Beshir; Safaa H Saleh
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

6.  Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015.

Authors:  Ardine M J Reedijk; Eline A M Zijtregtop; Jan Willem W Coebergh; Friederike A G Meyer-Wentrup; Konnie M Hebeda; C Michel Zwaan; Geert O R Janssens; Rob Pieters; Wouter J Plattel; Avinash G Dinmohamed; Josée M Zijlstra; Leontien C M Kremer; Pieternella J Lugtenburg; Auke Beishuizen; Henrike E Karim-Kos
Journal:  Br J Haematol       Date:  2020-02-06       Impact factor: 6.998

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.